Arvinas

Arvinas is a clinical-stage biotechnology company focused on developing pioneering therapies through their revolutionary PROTAC protein degradation platform. Dedicated to creating a new class of transformative medicines, Arvinas targets serious diseases such as cancer and neurological disorders. The company is committed to advancing targeted protein degradation as a promising area of medical research, aiming to offer new treatment options for patients and healthcare providers. Arvinas actively collaborates with academic experts and drug companies to accelerate their clinical programs. Rooted in innovative science and with a strong presence in New Haven, they are dedicated to improving patient outcomes through novel drug discovery and development.